Telix acquires ITM Isotope Technologies Munich
Analysis based on 7 articles · First reported Sep 21, 2026 · Last updated Sep 21, 2026
The deal reinforces the consolidation trend in radiopharmaceuticals, lifting sentiment for Telix and peers with radioisotope supply and late-stage therapeutic pipelines while pressuring competitors such as Novartis in neuroendocrine tumor therapies. Share issuance of $1.25 billion and assumed debt modestly dilute Telix equity but the acquired profitable isotope business and ITM-11 optionality support longer-term revenue and EBITDA growth expectations.
Telix Pharmaceuticals agreed to acquire privately held ITM Isotope Technologies Munich in a deal valued at up to $2.35 billion, comprising $1.65 billion upfront plus up to $700 million in contingent milestone payments. The upfront consideration includes $1.25 billion paid through 105.8 million Telix shares priced at $11.841 each, released as Nasdaq-listed American Depositary Receipts after escrow periods, while Telix assumes $302 million of ITM net debt and sellers bear $96 million of management equity rollover and transaction expenses. Upon completion, existing Telix shareholders would own about 76.3% and ITM shareholders about 23.7% of the combined company. ITM, founded in 2004 and based in Munich, Germany, manufactures radioisotopes including lutetium-177, actinium-225 and terbium-161, operates two GMP manufacturing sites and distributes across more than 65 countries, with 15 years of exclusive access to Bruce Power reactors in Canada via Isogen. Its lead asset ITM-11 (lutetium-177 edotreotide) for gastro-enteropancreatic neuroendocrine tumors completed Phase 3 development, though the United States — Food and Drug Administration reportedly rejected the application over third-party manufacturing issues, with resubmission planned. ITM generated $273 million revenue in 2025 with a 40% CAGR from 2021 to 2025, and management projects combined 2026 revenue above $1.3 billion. The transaction continues radiopharmaceutical sector consolidation involving Novartis, Eli Lilly and Company, AstraZeneca, Sanofi, Bristol Myers Squibb, Curium Pharma and Lantheus Holdings. Closing is expected by the end of fiscal 2026, subject to Telix shareholder and regulatory approvals, with an extraordinary general meeting scheduled for November 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard